Literature DB >> 10572346

Organizing ODIN: a case study in European academic co-operation. The ODIN Group.

C Dowrick1, J L Vázquez-Barquero, G Wilkinson, C Wilkinson, V Lehtinen, O S Dalgard, P Casey.   

Abstract

The European Commission is an increasingly important source of funding for international research projects and is due to announce its Framework 5 program early in 1999. The Outcomes of Depression International Network (ODIN), funded from the current EC Biomed 2 program, is a case study in European academic co-operation. Its organization has three key elements. First, engaging the principal investigators: this has involved identifying potential partners, ensuring reciprocity of interests, effective co-ordination, 'dividing the spoils' in advance, and setting up good personal and electronic communication systems. Second, an esprit de corps has been created amongst the researchers, maintaining contact and consistency, and promoting higher degrees. Third, ongoing problems including difficulties in negotiations with the EC, divergence of detailed study methods, and isolation and demoralization amongst researchers, have been addressed. ODIN may provide a useful model for researchers wishing to set up international collaborative groups.

Entities:  

Mesh:

Year:  1999        PMID: 10572346     DOI: 10.1016/s0924-9338(99)80739-1

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  2 in total

1.  The estimated incidence of depressive disorder and its determinants in the Finnish ODIN sample.

Authors:  Ville Lehtinen; Britta Sohlman; Teija Nummelin; Marja Salomaa; José-Luis Ayuso-Mateos; Christopher Dowrick
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-09-27       Impact factor: 4.328

2.  Is it always the same? Variability of depressive symptoms across six European countries.

Authors:  Sebastian Bernert; Herbert Matschinger; Jordi Alonso; Josep Maria Haro; Traolach S Brugha; Matthias C Angermeyer
Journal:  Psychiatry Res       Date:  2009-05-29       Impact factor: 3.222

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.